Postdoc at @LGlimcherMD lab @DanaFarber @harvardmed. PhD from @InamdarManeesha lab @JNCASR Working on tumor immunology (Immunotherapy, T and NK cell biology)
Thrilled to share our work from @LGlimcherMD lab @DanaFarber@harvardmed now published in @NatImmunol We identified Salt-Inducible Kinases (SIK) as novel drug targets for immunotherapy of ovarian cancer.
https://t.co/cmgUHyHyXj
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics@parkerici@CancerResearch@TheMarkFdn
https://t.co/Y37qbyw3F5
Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.
Astonishing translational work !
https://t.co/EvUmIGVLgs
Thrilled to join @IISERPune as a faculty member! My lab will pursue research on the neural circuits of emotion and defensive behaviors in mice. Looking forward to connecting with neuroscience community @INYAS_INSA 🧠🐭🐁💡
New-found immune cells called ‘ruptoblasts’ explode when triggered, ejecting toxic chemicals capable of delivering death to surrounding cells in just minutes. The cells’ discoverers say that this process, which they call ruptosis, seems to be a new form of cell death.
https://t.co/6JtcC1HjY0
3 new faculty positions have been advertised on ACTREC website under the jobs tab in the areas of cancer biology & translational cancer research. Pls spread the word & share the info with anyone interested!
@biopatrika@VoicesofIndAcad
Thrilled to share our work from @LGlimcherMD lab @DanaFarber@harvardmed now published in @NatImmunol We identified Salt-Inducible Kinases (SIK) as novel drug targets for immunotherapy of ovarian cancer.
https://t.co/cmgUHyHyXj
This work has been a wonderful collaborative effort! I am grateful to my postdoc supervisor and mentors for their constant support and guidance. Looking forward to seeing this work benefit patients in near future!
We found that SIK-specific inhibitors significantly improve anti-tumor cytokine production from healthy donor- and ascites-derived T cells in the presence of malignant ascitic fluid.
These findings were reproduced using patient samples. High expression of SIK2 and SIK3 is associated with poor survival in patients. Moreover, we observed that malignant immunosuppressive ascites strongly upregulates SIK expression in human T cells.
For decades, haemophilia meant a lifetime of painful injections and constant fear of bleeding.
But now, Indian scientists have taken a major leap forward.
In a first-of-its-kind trial, researchers in Bengaluru have successfully used gene therapy to help patients produce their own clotting factors.
Early results show drastically reduced bleeding, offering hope for a long-term solution — even a cure.
• Led by inStem Bengaluru & CMC Vellore
• Targets faulty gene causing haemophilia
• Patients showed near-zero bleeding episodes
• Reduces need for lifelong injections
On World Haemophilia Day, this breakthrough brings renewed hope for a future where no life is limited by this condition.
#HealthcareInnovation #MedicalBreakthrough #GeneTherapy #IndianScience #HopeInHealthcare
[Gene Therapy India, Haemophilia Treatment, Medical Innovation India, Biotechnology Breakthrough, Healthcare Advances]
Fascinating paper in @Nature today about how 🧬 variant impacting cyclin D3 alters malaria infectivity of red cells! https://t.co/DaWz6mOJtI, https://t.co/6nrbecLtv3 ... Follows up on some of our original studies from over 14 years ago: https://t.co/gRgZcPINRJ